We are live on ! Find out more
VPHM

VIROPHARMA INC
VPHM

Delisted

VPHM was delisted on the 23rd of January, 2014.

172 hedge funds and large institutions have $3.29B invested in VIROPHARMA INC in 2013 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 47 increasing their positions, 61 reducing their positions, and 69 closing their positions.

New
Increased
Maintained
Reduced
Closed

175% more funds holding in top 10

Funds holding in top 10: 411 (+7)

14% more capital invested

Capital invested by funds: $2.87B → $3.29B (+$416M)

10% less funds holding

Funds holding: 191172 (-19)

23% less repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 61

25% less first-time investments, than exits

New positions opened: 52 | Existing positions closed: 69

57% less call options, than puts

Call options by funds: $67.1M | Put options by funds: $155M

Holders
172
Holders Change
-19
Holders Change %
-9.95%
% of All Funds
4.99%
Holding in Top 10
11
Holding in Top 10 Change
+7
Holding in Top 10 Change %
+175%
% of All Funds
0.32%
New
52
Increased
47
Reduced
61
Closed
69
Calls
$67.1M
Puts
$155M
Net Calls
-$87.5M
Net Calls Change
-$82.9M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$477M +$10.8M +242,389 +3%
Vanguard Group
2
Vanguard Group
Pennsylvania
$205M +$1.81M +40,523 +1%
BFA
3
BlackRock Fund Advisors
California
$188M -$30.1M -672,327 -15%
OAM
4
Oxford Asset Management
United Kingdom
$153M +$137M +3,059,478 New
AQR Capital Management
5
AQR Capital Management
Connecticut
$142M +$127M +2,829,188 +17,507%
PCM
6
Pentwater Capital Management
Florida
$141M +$70.9M +1,585,000 +127%
HI
7
HBK Investments
Texas
$134M +$120M +2,691,527 New
WIC
8
Water Island Capital
New York
$124M +$111M +2,477,454 New
Adage Capital Partners
9
Adage Capital Partners
Massachusetts
$104M +$92.9M +2,078,299 New
Dimensional Fund Advisors
10
Dimensional Fund Advisors
Texas
$103M -$1.42M -31,651 -2%
State Street
11
State Street
Massachusetts
$96.8M -$2.94M -65,804 -3%
BIT
12
BlackRock Institutional Trust
California
$85.7M -$209K -4,671 -0.3%
PC
13
Paulson & Co
New York
$64.8M +$58.1M +1,300,000 New
GF
14
Gabelli Funds
New York
$60.6M +$54.4M +1,216,300 New
D.E. Shaw & Co
15
D.E. Shaw & Co
New York
$56.9M +$13.6M +303,435 +36%
Goldman Sachs
16
Goldman Sachs
New York
$52.4M -$26.7M -596,731 -36%
CS
17
Credit Suisse
Switzerland
$51.6M +$15.7M +351,816 +51%
FCM
18
Farallon Capital Management
California
$50.6M +$45.4M +1,015,000 New
Northern Trust
19
Northern Trust
Illinois
$49.9M -$882K -19,731 -2%
AAA
20
Alpine Associates Advisors
New Jersey
$45.9M +$41.2M +920,800 New
Barclays
21
Barclays
United Kingdom
$44.6M +$27.6M +617,763 +211%
ZDA
22
Zweig-DiMenna Associates
New York
$39.6M +$35.5M +794,184 New
GI
23
GAMCO Investors
Connecticut
$33.6M +$30.1M +673,900 New
CC
24
Carlson Capital
Texas
$33.4M +$29.9M +669,000 New
Bank of New York Mellon
25
Bank of New York Mellon
New York
$32.3M +$455K +10,182 +2%

VPHM Hedge Fund Activity: Q4 2013 in Review

172 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in VIROPHARMA INC (VPHM) for Q4 2013, worth a combined $3.29B — up 14% from $2.87B a quarter earlier.

Sellers outnumbered buyers: 69 funds closed out of VPHM and 52 opened new positions — a net loss of 17 holders — while 61 trimmed existing stakes and 47 added.

The largest buyer was Oxford Asset Management, opening a new position worth an estimated $137M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $220M sold.

  • 172 institutional investors held VIROPHARMA INC (VPHM) as of Q4 2013, down from 191 in Q3 2013.
  • Funds reported $3.29B of VIROPHARMA INC stock for Q4 2013, up 14% quarter-over-quarter.
  • 52 funds opened new VIROPHARMA INC positions in Q4 2013 and 69 closed out, a net change of -17 holders.
  • The largest VIROPHARMA INC buyer in Q4 2013 was Oxford Asset Management, an estimated $137M added.
  • The largest VIROPHARMA INC seller in Q4 2013 was Baker Bros. Advisors, an estimated $220M sold.

Based on aggregated 13F filings for Q4 2013.